|
|
Post by mnkdd on Aug 19, 2013 13:31:50 GMT -5
Sorry if this has been covered before, but thought it may be helpful to new members (and myself!). But could someone with more knowledge weigh the pros/cons of Biodel's oral insulin pill vis a vis Afrezza? Thanks!
Both insulins seem to be fast acting. Is Biod's current clinical trial "easier" to pass than MNKD's recent trial?
|
|
|
|
Post by johnnicholas14 on Aug 19, 2013 13:44:33 GMT -5
First, I believe its an injectable.
Also, I believe they are in Phase II, and success is easier in Phase II. They missed badly in Phase III with an earlier iteration of their drug.
|
|
|
|
Post by mnkdd on Aug 19, 2013 13:56:10 GMT -5
First, I believe its an injectable. Also, I believe they are in Phase II, and success is easier in Phase II. They missed badly in Phase III with an earlier iteration of their drug. Wow, can't believe I missed that. You're right-- the current phase II trial w/ BIOD123 is an injection. I was reading so much pumping re: the upcoming BIOD data that I assumed it was the oral pill they have in the works. So my next question is-- WTF? Why so much hoopla over a fast acting injectable insulin? Sure it may work faster than the current injectable insulins, but Afrezza certainly would be the obvious preferred choice. |
|
|
|
Post by liane on Aug 19, 2013 14:01:12 GMT -5
Looking very quickly (I don't follow BIOD), they have a sublingual formulation in Phase I.
|
|
|
|
Post by johnnicholas14 on Aug 19, 2013 15:23:05 GMT -5
First, I believe its an injectable. Also, I believe they are in Phase II, and success is easier in Phase II. They missed badly in Phase III with an earlier iteration of their drug. Wow, can't believe I missed that. You're right-- the current phase II trial w/ BIOD123 is an injection. I was reading so much pumping re: the upcoming BIOD data that I assumed it was the oral pill they have in the works. So my next question is-- WTF? Why so much hoopla over a fast acting injectable insulin? Sure it may work faster than the current injectable insulins, but Afrezza certainly would be the obvious preferred choice. Pills are probably basal. Afrezza is prandial. So no worries there  Afrezza, a monomer entering through the lungs will always be faster, unless you inject into a vein, but I doubt that will sell. However, it's hard to define a standard of care with insulin therapy, so BIOD may just be hoping for their own market niche. -Edited by Chris (moderator) -Edit reason: Confusing dialogue structure between MNKDD's comment and johnnicholas14's response; no additional words were added and only quote separation and spacing created. |
|
